CHGCY - Chugai's satralizumab nabs accelerated review status in U.S. for eye nerve disorder December, 19 2018 07:53 AM Chugai Pharmaceuticals Co. Ltd. ADR The FDA designates Chugai Pharmaceutical's (OTCPK:CHGCY) Phase 3-stage satralizumab, an IL-6 receptor humanized recycling antibody, a Breakthrough Therapy for the treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD), autoimmune dysfunctions primarily affecting the optical nerves and spinal cord. More news on: Chugai Pharmaceutical Co., Ltd. ADR, Roche Holding Ltd ADR, Healthcare stocks news, Read more ...